Log in to search using one of your social media accounts:

 

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis advances head-to-head superiority trials of Cosentyx ® versus Humira®* and proposed biosimilar adalimumab**
Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017. (Source: World Pharma News)
Source: World Pharma News - January 9, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 8, 2018 Category: Primary Care Source Type: news

Humira ’ s Best-Selling Drug Formula: Start at a High Price. Go Higher.
AbbVie ’ s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It ’ s gone up by 100 percent since then. (Source: NYT Health)
Source: NYT Health - January 6, 2018 Category: Consumer Health News Authors: DANNY HAKIM Tags: vis-multimedia Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Health Insurance and Managed Care Rheumatoid Arthritis AbbVie Inc Abbott Laboratories Source Type: news

Glenmark launches biosimilar Adalimumab in India
Glenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it the "best" selling drug in the world. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 4, 2018 Category: Pharmaceuticals Source Type: news

Arthritis Drugs Show How US Drug Prices Defy Economics Arthritis Drugs Show How US Drug Prices Defy Economics
Wholesale prices for Humira and Enbrel, the two most commonly used treatments for rheumatoid arthritis, known as RA, increased more than 70 percent in the past three years.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Amjevita (adalimumab-atto) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 7, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review
Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Sandoz says new clinical data support two biosimilars
ZURICH (Reuters) - Novartis' generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Efficacy and safety maintained in patients who switched from Humira ® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24. (Source: World Pharma News)
Source: World Pharma News - November 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

One year data showing CYLTEZO is equivalent to HUMIRA
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 6, 2017 Category: Research Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise
(Reuters) - AbbVie Inc on Friday said it expects its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie tops estimates, predicts Humira sales to hit $21bn by 2020
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 27, 2017 Category: Pharmaceuticals Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020
(Reuters) - AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Asacol vs. Humira
Title: Asacol vs. HumiraCategory: MedicationsCreated: 10/6/2017 12:00:00 AMLast Editorial Review: 10/6/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 6, 2017 Category: Drugs & Pharmacology Source Type: news

Humira Again Top-Selling Drug In U.S.
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 4, 2017 Category: General Medicine Source Type: news

Humira Again Top-Selling Drug In U.S.
Title: Humira Again Top-Selling Drug In U.S.Category: Health NewsCreated: 10/4/2017 12:00:00 AMLast Editorial Review: 10/4/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 4, 2017 Category: Rheumatology Source Type: news

Humira Again Top-Selling Drug In U.S.
Popular anti-inflammatory leads list of top-selling drugs for fifth straight year. (Source: WebMD Health)
Source: WebMD Health - October 3, 2017 Category: Consumer Health News Source Type: news

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023
(Reuters) - Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie makes peace with Amgen over Humira patents
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 28, 2017 Category: Pharmaceuticals Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates Amgen Acknowledges Validity of AbbVie's Extensive Intellectual Property Portfolio for... Biopharmaceuticals, Generics, Litigation, Licensing AbbVie, Amgen, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that it has reached a global settlement with AbbVie to resolve all ... Biopharmaceuticals, Generics, Litigation, Licensing Amgen, AbbVie, AMGEVITA, AMJEVITA, Humira, adalimumab, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA ™
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, a...
Source: Amgen News Release - September 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

RA Activity Stable After Prolonging Adalimumab Interval RA Activity Stable After Prolonging Adalimumab Interval
Reducing the frequency of adalimumab did not worsen disease activity or function in patients with rheumatoid arthritis and may safely lower treatment costs and risks for adverse events, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

Positive CHMP opinion for adalimumab biosimilar CYLTEZO
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 14, 2017 Category: Research Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira ®
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: (Source: World Pharma News)
Source: World Pharma News - September 4, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 29, 2017 Category: Drugs & Pharmacology Source Type: news

Adalimumab biosimilar CYLTEZO receives FDA approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 28, 2017 Category: Research Source Type: news

FDA Approves Second Humira Biosimilar, Cyltezo FDA Approves Second Humira Biosimilar, Cyltezo
Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Second Humira Biosimilar Approved
(MedPage Today) -- FDA announces approval of Cyltezo (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

Samsung, Biogen version of AbbVie's Humira approved in Europe
(Reuters) - Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - August 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Finger prick test allows patients taking autoimmune drug to avoid blood draws
(Wiley) A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira
Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira. (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

AbbVie to remain cautious on drug pricing, shares fall
(Reuters) - AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on Humira, Imbruvica demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on robust Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit rises 19 percent on Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported an 18.9 percent rise in quarterly profit on Friday on strong demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Interchangeability study on BI 695501 vs Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 26, 2017 Category: Research Source Type: news

CHMP Recommends Imraldi, a Biosimilar to Humira CHMP Recommends Imraldi, a Biosimilar to Humira
The CHMP has recommended Imraldi, a biosimilar to Humira.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

EU backs second biosimilar copy of Humira, world's top drug
FRANKFURT (Reuters) - European regulators have recommended approval of a second copy of AbbVie's rheumatoid arthritis drug Humira, the world's top-selling medicine, in a further boost for so-called biosimilars in the region. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Biosimilar for Adalimumab in Rheumatoid Arthritis New Biosimilar for Adalimumab in Rheumatoid Arthritis
A large multinational study compares the efficacy and safety of FKB327 biosimilar to adalimumab in active rheumatoid arthritis. But antidrug antibody levels raise questions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA ®
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid. (Source: World Pharma News)
Source: World Pharma News - June 15, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

biosimilar candidate shows clinical equivalence Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 14, 2017 Category: Research Source Type: news

AbbVie shares dip after it loses round in Humira patent fight
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 16, 2017 Category: Pharmaceuticals Source Type: news

Adalimumab Effective in Children and Adolescents With Severe Psoriasis Adalimumab Effective in Children and Adolescents With Severe Psoriasis
Adalimumab offers benefits over methotrexate in children and adolescents with severe chronic plaque psoriasis, according to a phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

JIA Uveitis Control Improved With Adalimumab + MTX JIA Uveitis Control Improved With Adalimumab + MTX
Adding adalimumab to MTX for treatment-resistant uveitis was associated with juvenile idiopathic arthritis improved disease control and enabled many patients to reduce or stop topical glucocorticoids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news